Status:
COMPLETED
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Lead Sponsor:
Galderma R&D
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12-35 years
Phase:
PHASE4
Brief Summary
This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morn...
Detailed Description
Same as above.
Eligibility Criteria
Inclusion
- Subjects with a minimum of 20 inflammatory lesions on the face;
- Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open and closed comedones) on the face, excluding the nose;
- Subject has a Global Severity Assessment
Exclusion
- 1\. Subjects with more than three nodulo-cystic lesions
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00671749
Start Date
December 1 2007
End Date
August 1 2008
Last Update
August 23 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Dermatology and Laser Surgery
Sacramento, California, United States, 95819
2
Derm Research, P.L.L.C.
Louisville, Kentucky, United States, 40217
3
Brodell Medical
Warren, Ohio, United States, 44483
4
Northwest Cutaneous Research Specialists
Portland, Oregon, United States, 97210